Evolving approaches to estimate risks of transfusion-transmitted viral infections: Incidence-window period model after ten years

Developments in Biologicals

Volumn 127, Issue , 2007, Pages 87-112

  Busch, M P ^a  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

Blood transfusion; Hepatitis B virus (HBV); Hepatitis C virus (HCV); Human immunodeficiency virus (HIV); Nucleic acid amplification testing (NAT)

Indexed keywords

BIOLOGICAL MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD; BLOOD TRANSFUSION; CONFERENCE PAPER; DISEASE TRANSMISSION; EPIDEMIOLOGY; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METHODOLOGY; RISK ASSESSMENT; THEORETICAL MODEL; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; HEPACIVIRUS; HEPATITIS; HEPATITIS B VIRUS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV-1; HUMANS; MODELS, THEORETICAL; RISK ASSESSMENT; SEROEPIDEMIOLOGIC STUDIES; VIRUS DISEASES;

EID: 34247100143     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (116)

1. Beeson PB: Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. JAMA 1943; 121: 1332-1334.
2. Grady GF, Charniers TC: Risk of post-transfusion viral hepatitis. N Engl J Med 1964; 271: 337-342.
3. Walsh JH, Purcell RH, Morrow AG, Chanock RM, Schmidt PJ: Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. JAMA 1970; 211: 261-265.
4. Domen RE: Paid-versus-volunteer blood donation in the United States: a historical review. Transfus Med Rev 1995; 9:53-59.
5. Blumberg BS, Alter HJ, Visnich S: A "new" antigen in leukemia sera. JAMA 1965; 191: 541-546.
6. Gocke DJ, Greenberg HB, Kavey NB: Hepatitis antigen. Detection of infectious blood donors. Lancet 1969; ii: 248-249.
7. Gocke DJ, Greenberg HB, Kavey NB: Correlation of Australia antigen with posttrasfusion hepatitis. JAMA 1970; 77: 877-879.
8. Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM Morrow AG, Schmidt PJ: Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972; 77:691-699.
9. Feinstone SM, Kapikian AZ, Purcell RH: Hepatitis A: detection by immune electron microscopy of a virus-like antigen associated with acute illness. Science 1973; 182: 1026-1028.
10. Stevens CE, Silbert JA, Miller DR, Dienstag JL, Purcell RH, Szmuness W: Serologic evidence of hepatitis A and B virus infections in thalassemia patients: a retrospective study. Transfusion 1978; 18: 356-360.
11. Dienstag JL, Feinstone SM, Purcell RH, Feinstone SM, Wong DC, Holland PV: Non-A, non-B post-transfusion hepatitis. Lancet 1977; i: 560-562.
12. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, et al; Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients. The Transfusion-Transmitted Viruses Study. N Engl J Med 1981; 04: 989-994.
13. Alter HJ, Purcell RH, Holland PV, Ailing DW, Koziol DE: Donor transaminase and recipient hepatitis. JAMA 1981; 246: 630-634.
14. Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmuness W, Kahn R, Werch J, et al: Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Int Med 1984; 101: 733-738.
15. Koziol DE, Holland PV, Alling DW, Melpolder JC, Solomon RE, Purcell RH, et al: Antibody to Hepatitis B core Antigen as a Paradoxical Marker for Non-A, Non-B Hepatitis Agents in Donated Blood. Ann Int Med 1986; 104: 488-495.
16. Infectious disease testing for blood transfusions. NIH Consensus Statement 1995 Jan 9-11; 13 (1): 1-27.
17. Alter HJ: To C or not to C: these are the questions. Blood 1995; 85: 1681-1695.
18. Ezzell C: Candidate cause identified of non-A, non-B hepatitis, [news] Nature 1988; 333: 195.
19. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-361.
20. Operskalski EA, Mosley JW, Tobler LH, Fiebig EW, Nowicki MJ, Mimms LT, Gallarda J, Phelps BH, Busch MP, for the Transfusion-Transmitted Viruses Study (TTVS) and the Retrovirus Epidemiology Donor Study (REDS): HCV Viral Load in anti-HCV-Reactive Donors and Infectivity for Their Recipients. Transfusion 2003; 43: 1433-1441.
21. Mimms LT, Mosley JW, Hollinger FB, et al: Transfusion-transmitted co-infection with human hepatitis B and hepatitis C viruses. Br Med J 1993; 307: 1095-1097.
22. Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP: Viral and Host Factors in Early Hepatitis C Virus Infection. Hepatology 2005; 42: 86-92.
23. Seeff LB, et al: Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33 (2): 455-463.
24. Busch MP: Insights into the Epidemiology. Natural History and Pathogenesis of Hepatitis C Virus Infection from Studies of Infected Donors and Blood Product Recipients. State of the Art Lecture, presented at 7th European Congress of the International Society of Blood Transfusion, Paris, July 2001. Transfusion Clinique et Biologique 2001; 8: 200-206.
25. Kleinman SH, Niland JC, Azen SP, Operskalski EA, Barbosa LH, Chernoff AI, Edwards VM, Lenes BA, Marshall GJ, Nemo GJ, et al: Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening. The Transfusion Safety Study/NHLBI Donor Repository. Transfusion 1989; 29 (7): 572-580.
26. Busch MP, Young MJ, Samson SM et al and the Transfusion Safety Study Group: Risk of human immunodeficiency virus transmission by blood transfusions prior to the implementation of HIV antibody screening in the San Francisco Bay Area. Transfusion 1991; 31: 4.
27. Perkins HA, Samson S, Busch MP: How well has self-exclusion worked? Transfusion 1988; 28: 601.
28. Selik RM, Ward JW, Buehler JW: Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982 through 1991. Transfusion 1993; 33: 890.
29. Donegan E, Stuart M, Niland JC et al and the Transfusion Safety Study Group: Infection with human immunodeficiency virus type I (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med 1990; 113: 733.
30. Busch M, Donegan E, Stuart M, Mosley JW, for theTransfusion Safety Study Group: Donor HIV-1 p24 antigenaemia and course of infection in recipients. Lancet 1990; i: 1342.
31. Donegan E, Lenes BA, Tomasulo RA, Mosley JW and the Transfusion Safety Study Group: Transmission of HTV-1 by components type and duration of shelf storage before transfusion. Transfusion 1990; 30: 851.
32. Busch MP, Operskalski EA, Mosley JW, Lee TH, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Strain DO: Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. J Infect Dis 1996; 174: 26.
33. Operskalski EA, Stram DO, Busch MP, Huang W, Harris M, Dietrich SL, Schiff ER, Donegan E, Mosley JW: Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol 1997; 146: 655.
34. Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, Stevens CE, Schiff ER, Dietrich SL, Mosley JW: Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis 1995; 172: 648.
35. Busch MP, Operskalski EA, Mosley JW et al and the Transfusion Safety Study Group: Epidemiologic background and long-term course of disease in human immunodeficiency virus type 1-infected blood donors identified before routine laboratory screening. Transfusion 1994; 34: 858.
36. Operskalski EA, Busch MP, Mosley JW, Stram DO: Comparative rates of disease progression among persons infected with the same or different HIV-1 strains. The Transfusion Safety Study Group. J Acquir Immune Defic Syndr Hum Retiovirol 1997; 15: 145.
37. Wilkinson DA, Operskalski EA, Busch MP, Mosley JW, Koup RA: A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis 1998; 178: 1163.
38. Diaz R, Sabino EC, Mayer A, Mosley JW, Busch MP: Dual Human Immunodeficiency Virus Type 1 Infection and Recombination in a Dually Exposed Transfusion Recipient. J Virol 1995; 69: 3273-3281.
39. Diaz RS, Zhang L-Q, Busch MP, Mosley JW, Mayer A: Divergence of HIV 1 Quasispecies in an Epidemiologie Cluster. AIDS 1997; 11: 415-422.
40. Zhang LQ, Diaz RS, Ho DD, Mosley JW, Busch MP, Mayer A: Host-Specific Driving Force in HIV-1 Evolution in vivo. J Virol 1997; 71: 2555-2561.
41. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L. Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS: Immunologie and virologie status after 14 to 18 years of infection with an attenuated strain of HTV-1. A report from the Sydney Blood Bank Cohort. N EngI J Med 1999; 340: 1715.
42. Busch MP, Collier A, Gernsheimer T, Carrington JD, Flanigan TP, Kashkari M, Kennedy M, Kumar PN, Lane TA, Mellors JW, Mohandas K, Pollard RB, Viele M, Yomtovian R, Holland PV, McCurdy PR: The Viral Activation Transfusion Study VATS: rationale, objectives, and design overview: Transfusion 1996; 36: 854.
43. Busch MP, Lee TH, Heitman J: Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 1992; 80: 2128.
44. Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman MM, Murphy EL, Kumar P, Kelley M, Flanigan TP, McMahon DK, Sacks HS, Kennedy MS, Holland PV, for the Viral Activation Transfusion Study Group: Leukocyte-Reduced Red Blood Cell Transfusions in Patients with Anemia and Human Immunodeficiency Virus Infection. The Viral Activation Transfusion Study: A Randomized Controlled Trial. JAMA 2001; 285: 1592-1601.
45. Ward JW, Holmberg SD, Allen JR et al: Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N Engl J Med 1988; 318: 473.
46. Nelson KE, Donahue JG, Muñoz A, Cohen ND, Ness PM, Teague A, Stambolis VA, Yawn DH, Callicott B, McAllister H, Reitz B A, Lee H, Farzadegan H, Hollingsworth CG. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HTV-1 and HTLV-I/II infections, [see comments]. Ann Intern Med 1992; 117 (7): 554-559.
47. Busch MP, Eble BE, Khayam-Bashi H, Murphy EL, Heilbron D, Kwok S, Sninsky JJ, Perkins HA, Vyas GN: Evaluation of Screened Blood Donations for Human Immunodeficiency Virus Type 1 Infection by Culture and DNA Amplification of Pooled Cells. N Engl J Med 1991; 325: 1-5.
48. Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B, and the HIV Seroconversion Study Group: Duration of Time from Onset of Human Immunodeficiency Virus Type 1 Infectiousness to Development of Detectable Antibody. Transfusion 1994; 34: 283-289.
49. Stramer SL, Heller JS, Coombs RW, Parry JV, Ho DD, Allain JP: Markers of HTV infection prior to IgG antibody seropositivity. Jama 1989; 262: 64-69
50. Alter HJ, Epstein JS, Swenson SG, VanRaden MJ, Ward JW, Kaslow RA, Menitove JE, Klein HG, Sandler SG, Sayers MH: Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors - an assessment of the efficacy of testing in donor screening. The HTV-Antigen Study Group. N Engl J Med 1990; 323 (19): 1312-1317.
51. Busch MP, Taylor PE, Lenes B A, Kleinman SH, Stuart M, Stevens CE, Tomasulo PA, Allain J-P, Hollingsworth CG, Mosley JW, and the Transfusion Safety Study Group: Screening of Selected Male Blood Donors for p24 Antigen of Human Immunodeficiency Virus Type 1. N Engl J Med 1990; 323: 1308-1312.
52. Korelitz JJ, Busch MP, Williams AE, and the Retrovirus Epidemiology Donor Study: Antigen Testing for Human Immunodeficiency Virus (HIV) and the Magnet Effect: Will the Benefit of a New HTV Test be Offset by the Numbers of Higher-Risk, Test-Seeking Donors Attracted to Blood Centers? Transfusion 1996; 36: 203-208.
53. Busch MP, Stramer SL: The Efficiency of HTV p24 Antigen Screening of US Blood Donors: Projections versus Reality. Infusionther Transfusionmed 1998; 25 (2): 5-8.
54. Donahue JG, Munoz A, Ness PM, Brown DE, Yawn DH, McAllister HA, et al: The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-373.
55. Nelson KE, Ahmed F, Ness P, Donahue JG: The incidence of post-transfusion hepatitis: Reply. New Engl J Med 1993; 328: 1280-1281.
56. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB: The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997; 11: 155.
57. Centers for Disease Control and Prevention. Persistent Lack of detectable HTV-1 antibody in a person with HTV infection-Utah, 1995. MMWR 1996; 45: 181-185.
58. Delwart EL, Orton S, Parekh B, Dobbs T, Clark K, Busch MP: Two Percent of HIV-Positive U.S. Blood Donors are Infected with Non-Subtype-B Strains. AIDS Res & Hum Retrovir 2003; 19: 1065-1070.
59. Delwart E, Kuhns MC, Busch MP: Surveillance of the Genetic Variation in Incident HTV, HCV, and HBV Infections in Blood and Plasma Donors: Implications for Blood Safety, Diagnostics, Treatment, and Molecular Epidemiology. J Med Virol, (Suppl) 2006 (in press).
60. Jongerius JM, Wester M, Cuypers HTM, van Oostendorp WR, Lelie PN, van der Poel CL, van Leeuwen EF: New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998; 38: 56-65.
61. Loussert-Ajaka I, Ly TD, Chaix ML, Ingrand D, Saragosti S, Courouce AM, Brun-Vezinet F Simon F: HIV-1/HTV-2 seronegativity in HTV-1 subtype O infected patients [see comments]. Lancet 1994; 343 (8910): 1393-1394.
62. Alter MJ, Margolis HS, Krawczynski K, et al, for The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team: The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-1905.
63. Busch MP, Watanabe KK, Smith JW, Hermansen SW, Thomson RA, for the Retrovirus Epidemiology Donor Study: False-Negative Testing Errors in Routine Viral Marker Screening of Blood Donors. Transfusion 2000; 40: 585-589.
64. Busch MP: Closing the Windows on Viral Transmission by Blood Transfusion, in Stramer SL (ed): Blood Safety in the New Millennium. AABB 2000 Emily Cooley Seminar Book. Bethesda MD, AABB Press, 2001, pp 33-54.
65. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685-1690.
66. th, Petersen LR; Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States [see comments]. New England Journal of Medicine 1995; 333 (26): 1721-1725.
67. Kleinman SH, Busch MP: Risks of Transfusion Transmitted Infection: Direct Estimation and Mathematical Modeling, in Contreras M (ed): New Aspects of Blood Transfusion, in Bailliere's Best Practice and Research in Clinical Haematology. London, Bailliere-Tindall, 2000, vol 13 (4), pp 631-649.
68. Glynn SA, Kleinman SH, Wright DJ, Busch MP, for the NHLBI Retrovirus Epidemiology Donor Study. International Application of the Incidence Rate/Window Period Model. Transfusion 2002; 42: 966-972.
69. Kleinman S, Alter H, Busch M, Holland P, Tegtmeier G, Nelles M, Lee S, et al: Increased detection of hepatitis C virus (HCV)- infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992; 32: 805-813.
70. Alter H: Transfusion-transmitted non-A, non-B and hepatitis C virus infections, in Rossi EC, Simon TL, Moss GS, Gould SA (eds): Principles of Transfusion Medicine. Baltimore, Williams & Wilkins, 1996, pp 687-698.
71. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB: Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. Transfusion 1995; 35: 903-910.
72. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR: Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68: 15-18.
73. Courouce AM, Le Marrec N, Girault A, Ducamp S, Simon N: Anti-hepatitis C virus (anti-HCV) sero-conversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 1994; 34: 790-795.
74. Mimms LT, Mosley JW, Hollinger FB, Aach RD, Stevens CE, Cunningham M, Vallari DV, Barbosa LH. Nemo GJ: Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. Brit Med J 1993; 307 (6912): 1095-1097.
75. Busch MP, Lee LLL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Read S, Dodd RY, Petersen LR: Time Course of Detection of Viral and Serological Markers Preceding HIV-1 Seroconversion; Implications for Blood and Tissue Donor Screening. Transfusion 1995; 35: 91-97.
76. Nubling CM, Unger G, Chudy M, Raia S, Löwer J: Sensitivity of HCV core antigen and RNA detection in the early infection phase. Transfusion 2002; 42: 1037-1045.
77. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R Giachetti C, Gallarda J, Busch MP: Dynamics of Viremia in Early Hepatitis C Virus Infection. Transfusion 2005; 45: 994-1002.
78. Fiebig EW, Heldebrant C, Smith RIF, Conrad A, Delwart EL, Busch MP: Intermittent Low-Level Viremia in Very Early Primary HIV-1 Infection. J AIDS 2005; 39: 133-137.
79. Murthy KK, Henrard DR, Eichberg JW, et al: Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999; 39: 688-693.
80. Roth WK, Weber M, Buhr S, et al: Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in Central Europe. Transfusion 2002; 42: 862-868.
81. Roth WK, Weber M, Petersen D, et al: Nucleic Acid Testing (NAT) for hepatitis B virus and anti-HBc testing increase blood safety. Transfusion 2002; 42: 869-875.
82. Matsumoto C, Tadokoro K, Fujimura K, et al: Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001; 41: 878-884.
83. Weusten JJ, van Drimmelen AA, Lelie PN: Mathematical modeling of the risk of HBV, HCV, and HIV transmission by window phase donations not detected by NAT. Transfusion 2002; 42: 537-548.
84. Alvarez M, Oyonarte S, Rodriguez PM, Hernandez JM: Estimated risk of transfusion-transmitted viral infection in Spain. Transfusion 2002; 42: 994-998.
85. Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM: Trends in residual risk of transfusiontransmitted viral infection in France between 1992 and 2000. Transfusion 2002; 42: 980-988.
86. Velati C, Romano L, Baruffi L, et al: Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion 2002; 42: 989-993.
87. Dodd RY, Notari EP, Stramer SL: Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-979.
88. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP, for the NHLBI Nucleic Acid Test Study Group: Detection of HIV-1 and HCV Infections Among Antibody-Negative Blood Donors by Nucleic Acid-Amplification Testing. N Engl J Med 2004; 351: 760-768.
89. Coste J, Reesink HW, Engelfriet CP, Laperche S, et al: ISBT International Forum: Implementation of Donor Screening for Infectious Agents Transmitted by Blood by Nucleic Acid Technology: Update to 2003. Vox Sang 2005; 88: 289-303.
90. Laperche S: Blood Safety and nucleic acid testing in Europe. Euro Surveill 2005; 10: 3-4.
91. Velati C, Fomiatti I, Baruffi L, Zanetti A: Impact of NAT in Italy in the three years following implementation (2001-2003). Euro Surveill 2005; 10: 12-14.
92. Pilonel J, Laperche S: Trends in risk of transfusion-transmitted viral infections (HTV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005; 10: 5-8.
93. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP: Comparative Sensitivity of HBV NATs and HBsAg Assays for Detection of Acute HBV Infection. Transfusion 2003; 43: 788-798.
94. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP: Dynamics of HTV Viremia and Antibody Seroconversion in Plasma Donors: Implications for Diagnosis and Staging of Primary HIV Infection. AIDS 2003; 17: 1871-1879.
95. Alter MJ, Mast EE: The epidemiology of viral hepatitis in the Untied States. Gastroenterol Clin North Amer 1994:23:437-455.
96. Sabino EC, Salles N, Saez-Alquezar A, Ribeiro-dos-Santos G, Busch MP, Chamone DF: Estimated Risk of Transfusion Transmitted HIV Infection in a Public Blood Bank in Sao Paulo, Brazil. Transfusion 1999; 39: 1152-1153.
97. Barreto CC, Sabino EC, Goncales TT, Laycock ME, Pappalardo BL, Salles NA, Wright DJ, Chamone DF, Busch MP: Prevalence, Incidence and Residual Risk of Human Immunodeficiency Virus among Community and Replacement First-Time Blood Donors in São Paulo, Brazil. Transfusion 2005; 45: 1709-1714.
98. Fang CT, Field SP, Busch MP, Heyns AduP: HTV-1 and HCV RNA Among South African Blood Donors: Estimation of Residual Transfusion Risk and Yield of Nucleic Acid Testing. Vox Sang 2003; 85: 9-19.
99. Heyns AduP, Benjamin RJ, Swanelvelder JPR, Laycock ME, Pappalardo BL, Crookes RL, Wright DJ, Busch MP: The Impact of a Structured Blood Safety Policy on HIV-1 Transfusion Transmission Risk in South Africa. JAMA 2006; 295: 519-526.
100. Kleinman SH, Busch MP: HBV: Amplified and Back in the Blood Safety Spotlight, [editorial] Transfusion 2001; 41: 1081-1085.
101. Schreiber GB, Glynn SA, Satten GA, Kong F, Wright DJ, Busch MP, Tu Y, Kleinman SH, for the Retrovirus Epidemiology Donor Study (REDS): HIV Seroconverting Donors Delay Their Return: Screening Test Implications. Transfusion 2002; 42: 414-421.
102. Seed CR, Cheng A, Ismay SL, et al: Assessing the accuracy of three viral risk models in predicting the outcome of implementing HFV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002; 42: 1365-1372.
103. Müller-Breitkreutz K: Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. Vox Sang 2000; 78: 149-157.
104. Koerner K, Cardoso M, Dengler Th, Kerowgan M, Kubanek B: Estimated risk of transmission of hepatitis C virus by blood transfusion. Vox Sang 1998; 74: 213-216.
105. International Forum: Implementation of donor screening for infectious agents transmitted by blood b nucleic acid technology. Vox Sang 2001; 82; 87-111.
106. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP: New Testing Strategy to Detect Early HIV-1 Infection for Use in Incidence Estimates and for Clinical and Prevention Purposes. Jama 1998; 280: 42-48.
107. Busch MP, Glynn SA, Stramer SL, et al: A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-264.
108. Yoshikawa A, Gotanda Y, Itabashi M, et al: Hepatitis B NAT virus-positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005; 88: 77-86.
109. Busch MP, Kleinman SK: Assessing the Impact of HBV NAT on Window Period Reduction and Residual Risk. J Med Virol (in press).
110. AuBuchon JP, Birkmeyer JD, Busch MP: Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 1997; 37: 45-51.
111. Jackson BR, Busch MP, Stramer SL, AuBuchon JP: The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-729.
112. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA et al: Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40.
113. Sanchez AM, Schreiber GB, Nass CC, Glynn SA, Kessler D, Hirschler N, Fridey J, Bethel J, Murphy EL, Busch MP, for the Retrovirus Epidemiology Donor Study (REDS): The Impact of Male-to-Male Sexual Experience on Risk Profiles of Blood Donors. Transfusion 2005; 45: 404-413.
114. Soldan K, Sinka K: Evaluation of de-selection of men who have had sex with men from blood donation in England. Vox Sang 2003; 84: 265-273.
115. Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo PA, Kleinman SH: Screening the Blood Supply for West Nile Virus RNA by Nucleic Acid Amplification Testing. N Engl J Med 2005; 353: 460-467.
116. Busch MP, Wright DJ, Tobler LH, Stramer SL, Custer B, Kleinman SH, Prince HE, Bianco C, Foster G, Petersen LR, Nemo G, Glynn SA: Estimated Proportion of the U.S. Population Infected with West Nile Virus during the 2003 Epidemic Based on National Blood Donor Screening Data. Emerg Infect Dis, 2005.